




RealRate

PHARMACEUTICAL 2017

ANI Pharmaceuticals INC
Rank 140 of 308



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of ANI Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANI Pharmaceuticals INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 96% points. The greatest weakness of ANI Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 92% points.

The company's Economic Capital Ratio, given in the ranking table, is 273%, being 28% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	103,007
Cost of Goods Sold	48,780
Intangible Assets	177,630
Liabilities, Current	31,948
Liabilities, Non-Current	0
Other Assets	31,229
Other Compr. Net Income	0
Other Expenses	33,772
Other Liabilities	121,268
Other Net Income	-11,401
Other Revenues	128,622
Property and Equipment	10,998
Research and Development	2,906
Selling, General and Administrative Expense	27,829

Output Variable	Value in 1000 USD
Assets	322,864
Liabilities	153,216
Expenses	113,287
Revenues	128,622
Stockholders Equity	169,648
Net Income	3,934
Comprehensive Net Income	3,934
BaseVar	364,695
ECR before Limited Liability	157%
Economic Capital Ratio	273%